Osaka, Japan. November 15, 2017 -We have been named as one of Forbes Asia’s “Best Under A Billion” companies for two years in a row. The “Best Under A Billion” list includes 200 best-performing and financially successful Asia-Pacific companies with revenues of between US$5 million and US$1 billion and consistent top- and bottom-line growth.
We were chosen from a universe of approximately 18,000 companies. The selection of the best 200 companies is based on earnings growth, sales growth, and shareholders' return on equity during the past 12 months and over three years.
We’re very honored that Forbes chose to recognise our efforts. Each and every executive and employee of Linical, ever conscious of our corporate social responsibility, and our two principal duties of “supporting innovative drug development” and “ensuring drug safety,” aspires to making the lives of people all over the world healthier and richer, by conducting our corporate activities with the utmost sincerity.
“Asia's 200 Best Under A Billion” for 2017 (Number of companies by country)
Japan: 38（13 companies for 2016）
China (Including Hong Kong): 70
Taiwan: 30
South Korea: 20
Vietnam: 9
Australia, Singapore: 6 each
Malaysia, Pakistan: 5 each
Thailand: 4
New Zealand, India: 3 each
Sri Lanka: 1